No Data
No Data
Can a $10,000 Investment in CRISPR Therapeutics Turn Into $1 Million?
Synthego Prevails In Patent Appeal Confirming Agilent CRISPR Patents Are Invalid
We're Not Very Worried About CRISPR Therapeutics' (NASDAQ:CRSP) Cash Burn Rate
AstraZeneca (AZN.US) CAR-T cell therapy has shown efficacy in some lupus patients.
AstraZeneca (AZN.US) stated that a few lupus patients experienced relief after receiving experimental cell therapy.
Crispr Extends Gains for the Seventh Consecutive Trading Day
$CRSP Stock Is up 4% Today. Here's What We See in Our Data.
Ma Yilong : follow herto doom